Genome Biology

official impact factor 6.89

Open Access Highly Access

Deciphering cellular states of innate tumor drug responses

Esther Graudens, Virginie Boulanger, Cindy Mollard, Régine Mariage-Samson, Xavier Barlet, Guilaine Grémy, Christine Couillault, Malika Lajémi, Dominique Piatier-Tonneau, Patrick Zaborski, Eric Eveno, Charles Auffray and Sandrine Imbeaud*

Genome Biology 2006, 7:R19 doi:10.1186/gb-2006-7-3-r19

Accesses  

  • Last 30 days: 48 accesses
  • Last year: 865 accesses
  • All time: 42049 accesses

Cited by

BioMed Central: 8 citations

Research   Open Access

NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines

Serges P Tsofack, Chantal Garand, Chris Sereduk, Donald Chow, Meraj Aziz, David Guay, Hongwei H Yin, Michel Lebel Molecular Cancer 2011, 10:145 (25 November 2011)

Research article   Open Access Highly Accessed

Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors

Marla H Daves, Susan G Hilsenbeck, Ching C Lau, Tsz-Kwong Man BMC Medical Genomics 2011, 4:56 (7 July 2011)

Research article   Open Access Highly Accessed

Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer

Vid Mlakar, Gašper Berginc, Metka Volavšek, Zdravko Štor, Miran Rems, Damjan Glavač BMC Cancer 2009, 9:282 (13 August 2009)

Methodology article   Open Access

Characterisation and correction of signal fluctuations in successive acquisitions of microarray images

Annie Glatigny, Hervé Delacroix, Thomas Tang, Nicolas François, Lawrence Aggerbeck, Marie-Hélène Mucchielli-Giorgi BMC Bioinformatics 2009, 10:98 (30 March 2009)

Review   Free Highly Accessed

Systems medicine: the future of medical genomics and healthcare

Charles Auffray, Zhu Chen, Leroy Hood Genome Med 2009, 1:2 (20 January 2009)

Systems approaches to medicine will transform the way drugs are developed and will enable medicine to become predictive, personalized, preventive and participatory.

Research article   Open Access Highly Accessed

The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome

Alison J Butt, C Marcelo Sergio, Claire K Inman, Luke R Anderson, Catriona M McNeil, Amanda J Russell, Marco Nousch, Thomas Preiss, Andrew V Biankin, Robert L Sutherland, Elizabeth A Musgrove Breast Cancer Research 2008, 10:R28 (29 March 2008)

Transcript profiling identified an estrogen-responsive target for the mammary oncogene c-Myc, HSPC111, which is overexpressed in breast cancer cells and is associated with adverse patient outcome.

Research   Open Access Highly Accessed

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine

Blanca Segura-Pacheco, Enrique Perez-Cardenas, Lucia Taja-Chayeb, Alma Chavez-Blanco, Alma Revilla-Vazquez, Luis Benitez-Bribiesca, Alfonso Duenas-González Journal of Translational Medicine 2006, 4:32 (7 August 2006)

Hypothesis   Open Access

Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?

Carlos Perez-Plasencia, Alfonso Duenas-Gonzalez Molecular Cancer 2006, 5:27 (10 July 2006)